In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivaldi Biosciences Inc.

www.vivaldibiosciences.com

Latest From Vivaldi Biosciences Inc.

Vaccines Chess Game Continues With Baxter Sale To Pfizer

Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, November 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.

BioPharmaceutical Medical Device

BioNotebook: Dyax, MacroGenics, Vivaldi and Rexahn

Dyax prices $60m offering; MacroGenics surges in first day of trading; Vivaldi acquires vaccine assets; and Rexahn licenses academic drug delivery platform.

Infectious Diseases Cancer

BIO Looks To Colorado Task Force In Push Against Universal Vaccine Purchase Program

The biotech industry is concerned that a pending Colorado bill moves toward shifting vaccine purchases for insured patients from the private to the public sector, but supports the bill’s establishment of a task force to examine ways to increase immunization rates.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vivaldi Biosciences Inc.
  • Senior Management
  • Douglass Given, MD, PhD, Chmn., Pres. & CEO
    William Wick, COO & CFO
    Bin Lu, PhD, VP, R&D
  • Contact Info
  • Vivaldi Biosciences Inc.
    Phone: (970) 492-4365
    3185-A Rampart Rd., Campus Delivery 0922
    Fort Collins, CO 80523-0922
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register